Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus JENCYCLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus JENCYCLA.
ENSKYCE vs JENCYCLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive